Concepedia

Vijayalakshmi Natarajan

VN

Statistics

Publications

4

Citations

177

H-Index

4

Active since

2002

Affiliations

Pfizer (United States)(Current)

Vijayalakshmi Natarajan is an author at Pfizer (United States) specializing in drug discovery, potency optimization, and enzyme inhibition.

Publications per year

2002–2023

4

Publications

4

Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors

Michael A. Letavic, Matt Z. Axt, John T. Barberia et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 75 citations · Full text

, , +8

Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13

Mark C. Noe, Vijayalakshmi Natarajan, Sheri L. Snow et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 44 citations · Full text

, , +7

Discovery of 3-OH-3-methylpipecolic hydroxamates: Potent orally active inhibitors of aggrecanase and MMP-13

Mark C. Noe, Vijayalakshmi Natarajan, Sheri L. Snow et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 37 citations · Full text

, , +8

Time Series Modeling and Forecasting Using Autoregressive Integrated Moving Average and Seasonal Autoregressive Integrated Moving Average Models

Vignesh Arumugam, Vijayalakshmi Natarajan · Instrumentation Mesure Métrologie · 2023 · 21 citations · Full text

, , +16

1–4 of 4